Retatrutide
Not approved anywhere; US filing planned for early 2027.
A weekly injection that acts on three hormone receptors at once. It has produced the largest weight loss yet seen in trials. Not approved anywhere, and heavily traded on the . Made by Eli Lilly, also called LY3437943, Triple G and Reta.
What the evidence shows
Side effects and risks
Who should avoid it: Anyone outside a clinical trial.
How it works
- Where it acts
- GIP, GLP-1 and glucagon receptors.
- What it changes
- GLP-1 and GIP cut appetite. Glucagon adds energy use and pushes the liver to burn fat.
- What people notice
- In trials, the largest weight loss of any drug so far. Stomach side effects and a faster heart rate were reported.
How it has been given in trials
Weekly injection under the skin, stepped up over months to 4, 9 or 12 mg. There is no approved dose.
Getting it in the United States
The legal route for Retatrutide
Not approved. The only lawful way to get it is to join a clinical trial.
Lilly clinical trial enrolment
The only lawful route is a Lilly-sponsored trial. Lilly plans to file for approval in early 2027, so no approved product exists yet.
Source: Axios, 2026-08
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Online research-use-only sellers
Dozens of websites sell vials labelled for research while marketing weight loss, often via influencer links. Lilly and FDA call this unlawful. Lilly testing found wrong strengths, other drugs such as insulin, and likely non-sterile product.
Source: pharmaphorum, 2026-08
Med spas and compounding pharmacies
Some med spas, wellness clinics and compounders supply it. FDA says retatrutide cannot be used in compounding. Lilly sued six US sellers in 2026-08 and referred over 200 parties to authorities.
Source: Axios, 2026-08
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
What users report
Recurring themes in public forum posts, unverified and with no comparison group.
Reported benefits
- Stronger appetite suppression than tirzepatide
- Fast loss, and more energy than on other GLP-1 drugs
Reported problems
- Racing heart and poor sleep
- Sore or tingling skin, matching the trials
- Nausea
- Fear of fake vials and dosing mistakes
Every report outside a trial involves an unregulated product, so the dose and even the contents are uncertain.
More contextCase reports, what public figures say, videos and articles, when options run out and the chemistry
Case reports
From journals, regulators and studies of users. One case proves little.
Mixed resultcase series - 652 people - 2026
Preprint, not peer reviewed. US health records showed 652 people with retatrutide exposure, about 71 percent outside trials. Non-trial users lost about 7 percent of weight versus 15.5 percent in trial participants. Heart rate rose. Product contents were unknown.
Source: nference preprint, 2026-08
Mixed resultstudy of online posts - 2026
Researchers analysed 1,774 Reddit posts on retatrutide and 12,392 bodybuilding forum posts. Weight trainers framed GLP-1 drugs as aids to insulin sensitivity and lean mass and a safer option than insulin. Authors flagged misinformation and polysubstance use.
Harm reportedcase series - 36 people - 2026
Public Citizen counted 36 FDA adverse event reports naming retatrutide from 2025 to May 2026. At least 14 involved hospital stays and 3 were called life-threatening. Reported events included vomiting, fast heart rate and ketoacidosis.
Source: Public Citizen report, 2026-06
Harm reportednews-reported case - 1 person - 2026
A bodybuilding influencer was diagnosed with acute necrotising pancreatitis after months of gray-market retatrutide use, according to a magazine account cited by Public Citizen.
Source: Public Citizen report, 2026-06
What experts and influencers say
Paraphrased from the linked sources.
In August 2026 called on online platforms, payment companies and regulators to shut down the black market in retatrutide, which is still in trials and approved nowhere.
Source: Eli Lilly statement, 12 Aug 2026
Lead author of the TRIUMPH-1 phase 3 paper. Her team reported large weight loss with less knee pain and sleep apnea, and argued for treating obesity to a defined target.
Source: HCPLive, 2026-09
Ania JastreboffWebsiteRecommends
Photo source: medicine.yale.edu
Reported as saying trial patients keep losing weight without a plateau because the drug is so potent, and warning that nobody knows what gray-market vials contain.
Eric TopolWebsiteMixed view
In July 2026 acted against 71 sources selling unapproved peptide slimming products and referred 14 social media influencers to the media regulator for promoting them. It named retatrutide as unapproved for any use in the UAE.
Source: Gulf News, 25 Jul 2026
Emirates Drug EstablishmentSourceWarns against
Reported as saying he tried retatrutide before major shows and that it worked very well for stripping fat. He won a pro show in 2025.
Nick WalkerWikipediaRecommendsSays they used it
Photo source: 구본웅 / CC BY-SA 4.0
Told Axios that Lilly's suits rely on state and consumer-protection law, not patents, and acknowledged that some gray-market products do help certain people lose weight.
Source: Axios, 2026-08
Edgar AsebeyWebsiteMixed view
Photo source: frierlevitt.com
Called black-market retatrutide unverified, unapproved and not a medicine as Lilly sued six US sellers. Lilly said tested products had wrong strengths or other ingredients such as insulin.
Source: pharmaphorum, 2026-08
David HymanWebsiteWarns against
Money: Lilly executive; Lilly owns retatrutide
Photo source: the-asci.org
Reported as posting on TikTok that retatrutide made it hard for him to gain body fat.
Dawson WeissWebsiteRecommendsSays they used it
Photo source: streamrecorder.io
Reported as discouraging retatrutide use over contamination and unknown risks, while taking a harm-reduction approach with patients who use it anyway.
Christle GuevarraInstagramWarns against
Wrote a report finding FDA warning letters to 14 retatrutide sellers had little effect, with most still advertising peptides. He urged seizures, injunctions and prosecutions.
Source: Public Citizen, 2026-06
Peter WhoriskeyWebsiteWarns against
Photo source: citizen.org
Co-wrote a Lancet comment calling illicit injectable peptide use among young people an emerging public health issue. Named BPC-157, CJC-1295 and retatrutide and urged curbs on influencer and affiliate marketing.
Source: The Medical Republic, 2026-05
Jason NagataSourceWarns against
Reported that US poison center reports of retatrutide exposure rose about tenfold from late 2025 to spring 2026 as people bought unapproved vials online, with some who skipped slow dose increases ending up in emergency rooms.
Source: The Washington Post via Jewish World Review, 2026-08
Shane O'NeillWebsiteWarns against
Photo source: washingtonpost.com
After the MHRA raided an illegal factory making retatrutide and tirzepatide pens, he said such products are made with no regard for safety and urged people to avoid the black market.
Source: Euronews, 2025-10
Wes StreetingInstagramWarns against
Compared retatrutide's potential significance to the discovery of insulin and noted possible gains in liver fat, blood pressure and cholesterol, but said most phase 3 trials are unfinished and conclusions are premature.
Source: The Washington Post via Jewish World Review, 2026-08
Harpreet BajajWebsiteMixed view
Photo source: lmc.ca
Said in a YouTube video that side effects from a gray-market retatrutide jab put him in hospital, according to Channel 4 News.
Source: Channel 4 News, 2025-10
Adrian CrookInstagramWarns againstSays they used it
Reacting to an RTE investigation that bought real retatrutide from an unlicensed seller offering to inject it, he called the practice mad and said a doctor doing it would lose registration.
Source: RTE, 2024-12
Donal O'SheaWebsiteWarns against
Photo source: irishtimes.com
After the TGA listed retatrutide among unapproved peptides, he said buyers have no assurance about contents, dose or sterility, and that patients are offered products through gyms.
Source: RACGP newsGP, 2026-04
James KellyWebsiteWarns against
Photo source: drjameskelly.com.au
Stated that retatrutide has no UK authorisation and cannot be legally supplied outside clinical trials. Its enforcement unit raided several illegal manufacturing sites between late 2025 and mid 2026.
Source: The Pharmacist, Aug 2026
Led the Northampton raid that seized over 2,000 unlicensed pens labelled retatrutide or tirzepatide. Described it as a landmark result and a major blow to the illegal trade.
Source: Medical Republic, Nov 2025
Andy MorlingWebsiteWarns against
Photo source: bbc.co.uk
Warned that strong trial results are not approval. Listed red flags: sales by direct message, payment by bank transfer and sellers who never ask about medical history.
Source: The Pharmacist, Aug 2026
Abdal AlviSourceWarns against
Money: Works for a private online pharmacy that sells licensed weight-loss medicines
Told the public not to buy or use peptides sold online. Reported serious cases with hospital stays, notably after retatrutide. Ordered several products presented as GLP-1 drugs off the market in July and August 2026.
Source: ANSM, Jul 2026
Told AFP that many of these molecules have never been tested in humans and that self-experiment stories shared online carry no scientific weight.
Source: Sud Radio / AFP, Aug 2026
Armelle RancillacWebsiteWarns against
Photo source: college-de-france.fr
Wrote that the 2026 French alert goes beyond the GLP-1 fakes flagged in 2025, and that some products are passed off as food supplements or carry research-only labels that buyers should not trust.
Source: Vidal, Jul 2026
Irene DrogouWebsiteWarns against
Photo source: lequotidiendumedecin.fr
Imposed a trade ban on two peptide websites and has more investigations open. Says selling medicines without a licence is illegal even with a research-only label, and calls buying them life-threatening.
Source: AVROTROS Radar, Mar 2026
IGJ (Health and Youth Care Inspectorate)SourceWarns against
Received two reports in autumn 2025. One person needed intensive care with brain, kidney and eye damage from high blood pressure, possibly after a retatrutide injection. The other involved illegally sold semaglutide.
Source: AVROTROS Radar, Mar 2026
Told consumers not to buy retatrutide offered online for research purposes. Also criticised the maker's early publicity for unreviewed trial results as premature and a form of advertising for an unlicensed drug.
Source: Test-Aankoop, Jul 2026
Test-AankoopSourceWarns against
Told the public not to inject peptides bought online. Said unauthorized products are illegal, unproven and may cause organ damage, clots or tumour growth. A research-use-only label does not make them legal.
Source: Health Canada advisory, 2026-04
Health CanadaSourceWarns against
Wrote that human evidence for BPC-157 amounts to three tiny reports. Called self-injection of online peptides high-risk, uncontrolled self-experimentation and asked for blinded placebo-controlled trials.
Stuart PhillipsWebsiteWarns against
Photo source: science.mcmaster.ca
Reported treating severe anaphylaxis from an unidentified peptide and poisons calls about teenagers as young as 14 vomiting after retatrutide. Also listed liver injury and injection-site abscesses. Backs harm minimisation.
Source: Australian Pharmacist, Jul 2026
Angela ChiewWebsiteWarns against
Photo source: apsi-databank.sydney.edu.au
Told a pharmacy journal that compounded peptides get no pre-market checks and that sterility failures in injectables can cause serious harm. Says it does not decide whether a doctor should prescribe a peptide.
Source: Australian Pharmacist, Aug 2026
Therapeutic Goods AdministrationSourceWarns against
After liver injury cases linked to a product labelled retatrutide, said contaminants may be adding to the toxicity. Asked doctors to check liver tests and ask patients about peptides bought online.
Source: newsGP, RACGP, 2026-06
Caroline McElnayWebsiteWarns against
Photo source: rnz.co.nz
Said the most alarming trend is peptides sold as stacks, because scientists do not fully understand how they interact or what they do over the long term.
Source: The Washington Post via Jewish World Review, 2026-08
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
Lilly's 'triple-G' drug leads to bariatric-surgery levels of weight loss in trial
Elaine Chen, national biotech reporter
Covers Lilly's phase 3 retatrutide results, with near bariatric-surgery weight loss at the top dose alongside a notable share of people stopping over side effects.
First big phase 3 readout, with the dropout caveat
New data on Eli Lilly's 'triple-G' drug leave open questions on heart benefit
Elaine Chen, national biotech reporter
Retatrutide cut weight sharply in people with severe obesity and heart disease but did not significantly reduce major heart events in this trial.
A sober check on the headline weight-loss numbers
Illegal weight loss drug floods SA
Hasina Kathrada, journalist
Investigates a South African black market for unapproved peptides sold as retatrutide, with regulators warning of non-sterile, mislabelled or contaminated products.
Shows what the gray market actually looks like
When options run out
Uses people turn to when standard treatment has failed.
Knee osteoarthritis pain with obesity
- Who
- People with obesity and painful knee arthritis who want pain relief through large weight loss.
- Evidence
- TRIUMPH-1 phase 3, 2,339 adults over 80 weeks. Knee pain scores fell more with retatrutide than placebo. Company-run trial.
- Route
- Lilly phase 3 trials only
Source: HCPLive, 2026-09
Obstructive sleep apnea with obesity
- Who
- People with obesity and sleep apnea seeking fewer breathing pauses at night.
- Evidence
- In TRIUMPH-1, breathing pauses per hour fell far more with retatrutide than placebo at 80 weeks. Low blood pressure symptoms were reported.
- Route
- Lilly phase 3 trials only
Source: HCPLive, 2026-09
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Amino-acid sequence
Position 17 carries a fatty-acid side chain. Ringed tiles are amino acids not found in natural proteins.
Questions people ask
Is retatrutide FDA approved?
No. It is not approved anywhere, and a US filing is planned for early 2027. FDA sent warning letters to sellers in August 2026.
How much weight do people lose on retatrutide?
In TRIUMPH-1 (2,339 people, 80 weeks), average loss on the top dose was 28.3% among people who stayed on it and 25.0% counting everyone, against 2.2% and 3.9% on placebo.
What are the side effects of retatrutide?
On the top dose, nausea affected 42% and vomiting 25%. Abnormal skin sensations such as tingling, burning or soreness to touch affected 12.5%, against 0.9% on placebo, and about 11% stopped because of side effects.
Is it safe to buy retatrutide online?
Vials sold online are unapproved and of unknown quality, so the dose and even the contents are uncertain. FDA adverse-event reports rose from 10 in all of 2025 to 26 in the first five months of 2026.
Is retatrutide stronger than tirzepatide?
Its trials have produced the largest weight loss of any drug so far. Users outside trials report stronger appetite suppression than on tirzepatide, but they use unregulated products of uncertain dose and content.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
- Eli Lilly: TRIUMPH-1 results (21 May 2026)
- Eli Lilly: TRIUMPH-4 results (11 Dec 2025)
- Eli Lilly: TRIUMPH-2 and TRIUMPH-3 results (23 Jul 2026)
- Eli Lilly: TRANSCEND-T2D-1 results (19 Mar 2026)
- Finnrick: retatrutide test counts
- Frier Levitt: Lilly's retatrutide lawsuits (18 Aug 2026)
- Health Canada: unauthorized injectable peptides (1 Aug 2025)
- Pharmacy Daily: TGA peptide raids (18 Aug 2026)
- MHRA: record seizure of illicit weight-loss pens (24 Oct 2025)
- Public Citizen: the retatrutide trade (16 Jun 2026)
- FDA: concerns about unapproved GLP-1 drugs
Structure: PubChem